Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Text reminders may boost statin refills in heart patients

NCT ID NCT07522645

Disease control Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study will test whether sending reminders by text, email, or secure patient portal messages helps people with heart disease or diabetes refill their statin prescriptions. About 22,000 adults who have not refilled their statin in the last 3 months will receive one of these messages or usual care. Researchers will track who refills within 14 days and may send a second message using a different method if the first one doesn't work.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioral intervention (text messages, secure portal messages, or email reminders)
What this could lead to
If successful, this could show that simple reminders through existing communication channels improve medication adherence, potentially reducing heart attacks and strokes.
What could go wrong
This is a large but early-stage behavioral study, not a drug trial. Results depend on patient engagement and may not apply to other health systems or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 22,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Age ≥18 years 2. Active Kaiser Permanente Northern California (KPNC) membership 3. Diagnosis of atherosclerotic cardiovascular disease (ASCVD) or diabetes and inclusion in the Preventing Heart Attacks and Strokes Everyday (PHASE) Registry 4. No statin prescription fill within the prior 3 months 5. Statin adherence \<80% in the prior 12 months 6. Active kp.org account within the past 12 months 7. Valid email address and text-capable phone number on file Exclusion Criteria 1. Documented allergic reaction or contraindication to statin therapy 2. Receiving hospice care 3. Medicare beneficiaries 4. Other exclusions applied per operational standard practice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCVD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCVD Diabetes

Contacts and locations

Locations

  • Kaiser Permenante Northern California

    Pleasant Hill, California, 94588, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.